A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
Kyoichi KairaAtsuto MouriShingo KatoKenichi YoshimuraHiroshi KagamuKunihiko KobayashiPublished in: BMC cancer (2020)
The secondary endpoints are the feasibility, objective response, PFS, overall survival, and adverse events.